Warning: Missing argument 1 for get_pagelink_by_slug(), called in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/header.php on line 111 and defined in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/admin/functions-theme-basic.php on line 98

機関誌『日中医学』

特集:増加する日中における呼吸器疾患の研究と臨床Update

巻頭言 呼吸器疾患の多元化

島根大学内科学講座呼吸器・臨床腫瘍学 教授
礒部 威

COPD:中国における研究と臨床の最前線

中日友好病院呼吸器・危重症医学科 医師
黄 可

Cutting-Edge of Current Research and Clinical Activity for COPD in China
 

【Abstract】
Chronic obstructive pulmonary disease(COPD)leads to high disease burden in China, but needs further prevention and management. In recent years, Chinese experts has gained important progress in research and clinical work of COPD, including disease burden survey, risk factors analysis, phenotype research and drug treatment. This review summarized these progresses in recent years.

【Key words】
Chronic obstructive pulmonary disease, disease burden, phenotype, treatment

肺高血圧症:中国における研究と臨床の最前線

西安交通大学第二附属病院 副研究員
王 蕾

Cutting-Edge of Current Research and Clinical Activity for Pulmonary Hypertension in China
 

【Abstract】
In the past 10 years, pulmonary hypertension research in China has made great progresse. With the in-depth research on its pathogenesis and the development of guidelines, the treatment behavior of Chinese clinicians has been standardized, and the clinical treatment of pulmonary hypertension in China has been improved, which thereby significantly improving the prognosis of Chinese pulmonary hypertension patients, and survival rate almost reaches the level of developed countries. This article will summarize the current situation of research and clinical treatment for pulmonary hypertension in China.

【Key words】
pulmonary hypertension, treatment, research

COPD:日本における研究と診療の最前線

横浜市立大学大学院医学研究科呼吸器病学 主任教授
金子 猛

Cutting-Edge of Current Research and Clinical Activity for COPD in Japan
 

【Abstract】
We introduce three relevant topics from our studies in the diagnosis and treatment of COPD. First, heme oxygenase-1, an inducible protein activated in systemic infl ammatory conditions by oxidant stress, shows efficacy as a serum biomarker for predicting the risk of developing COPD. Second, our systematic review of the clinical trials comparing LAMA/LABA and ICS/LABA to prevent COPD exacerbation is essential for understanding the positioning of ICS. Last, clarithromycin (CAM)suppression of the IL-13-induced MUC5AC expression pathway demonstrates the mechanism by which CAM reduces airway hypersecretion in COPD patients.

【Key words】
heme oxygenase-1, LAMA/LABA, ICS/LABA, MAC5AC, macrolide antibiotics, clarithromycin

肺高血圧症:日本における研究と臨床の最前線

順天堂大学大学院医学研究科呼吸器内科学
長岡鉄太郎※1、栗山祥子、堤建男
※1.准教授(責任著者)

Cutting-Edge of Current Research and Clinical Activity for Pulmonary Hypertension in Japan
 

【Abstract】
Recent advances on the treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are remarkable. Results of translational researches from Japan indicate the novel mechanism of disease progression. High dose epoprostenol and balloon pulmonary angioplasty established in Japan are becoming the new standard therapy in global. Previous basic and clinical researches from Japan contribute to the development of therapeutic strategy for those pulmonary hypertension.

【Key words】
pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, pulmonary hypertension with chronic lung disease, epoprostenol, balloon pulmonary angioplasty

 

架け橋 
      
      

国際協力を通した中国との出会い
東京女子医科大学国際環境・熱帯医学講座 教授/講座主任
杉下智彦

笹川生 in China 
     
     

COVID-19との闘い ~ 少年の日の心を取り戻させた湖北支援
中国医科大学附属第一病院胸部外科 副教授、副主任医師
李 文雅

あとがき 広報委員会委員  高橋和久
機関誌『日中医学』投稿原稿募集の
お知らせ